Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (242.930 €): Vorhersage der kardiotoxischen Induzierten Kinase-Inhibitoren: Von der Systembiologie zur Systempharmakologie Hor05.05.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Vorhersage der kardiotoxischen Induzierten Kinase-Inhibitoren: Von der Systembiologie zur Systempharmakologie
Kinase inhibitors (KIs) are a major class of highly effective anti-cancer drugs. Unfortunately, therapeutic use of KIs is often associated with cardiotoxicity (CT), a serious adverse condition which limits their use. This fellowship aims to develop mathematical systems pharmacology models for KI-induced CT. These models will be used to identify predictive CT signatures that will allow to decrease CT risk of new KIs. This innovative multi-disciplinary approach consists of integrating mathematical systems pharmacology modelling, with state-of-the-art experimental data generation. To this aim, KIs with different magnitudes of CT will be selected based on clinical adverse event databases. Human cardiomyocytes derived from pluripotent stem cells will then be treated with the selected KIs and in combination with CT modifying drugs. The effect of these treatments on changes on untargeted mRNA and protein expression will be measured and then analyzed using network modelling. This approach allows identification of key regulatory proteins. The selected proteins will then be quantified over time along with cardiomyocyte health markers. With this data, dynamical models will be developed to capture the relationship between exposure to KIs and the effects on protein expression and cardiomyocyte health over time. Ultimately these models will allow generation of predictive network-based dynamically-weighted signatures for CT. The fellow aims to establish himself as independent researcher in systems pharmacology. Training in state-of-the-art computational and experimental technologies at the leading systems pharmacology group at Mount Sinai in New York will fundamentally strengthen and broaden the experience of the fellow. This project will significantly contribute consolidate the career track of the fellow, foster future collaboration between Mount Sinai and Leiden University, and disseminate training in Europe.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | ? |
| UNIVERSITEIT LEIDEN | 242.930 € |
Quelle: https://cordis.europa.eu/project/id/661588
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, USA.
Die Visualisierungen zu "ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - EU-Förderung (242.930 €): Vorhersage der kardiotoxischen Induzierten Kinase-Inhibitoren: Von der Systembiologie zur Systempharmakologie"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
